Dongkook Pharmaceutical Strengthens ESG Management... Establishes 'ESG Committee and Permanent Working Organization'

Establishing Management Foundations by Environment, Social, and Governance Sectors
Plans to Publish Future Sustainability Management Reports

Dongkook Pharmaceutical Jincheon Plant.

[Asia Economy Reporter Lee Gwan-ju] Dongkook Pharmaceutical is strengthening ESG management for a sustainable future.

On the 16th, Dongkook Pharmaceutical announced that it will promote ESG projects in the areas of Environment, Social, and Governance, establish an ESG committee and a permanent working organization, and pursue transparent and accurate information disclosure.

In the Environment sector, since September last year, the company has started an energy efficiency project in cooperation with the global environmental company Veolia of France, making efforts to reduce energy consumption and improve the operation efficiency of wastewater treatment plants. Through three collaborative projects?waste biogas recycling, carbon emission reduction, and wastewater treatment plant optimization?Dongkook Pharmaceutical expects to achieve optimized energy consumption management and obtain the international standard ISO 14001 certification.

In the Social sector, the company has established an emergency response system for fires, safety accidents, infectious diseases, and environmental accidents, as well as a safety management system for outsourced construction companies, applying these to each business site. Additionally, it is strengthening internal training to comply with safety accident prevention measures and response regulations, striving to achieve zero accidents and zero injuries, while pursuing the acquisition of the related international standard ISO 45001 certification.

In the Governance sector, since 2019, Dongkook Pharmaceutical has established a social responsibility and ethical management system and an anti-corruption management framework, obtaining the international standard ISO 37001 certification for anti-corruption management systems after a strict review process. This year, the company plans to conduct a renewal audit for ISO 37001 re-certification and aims to continuously enhance the level of company-wide ethical management practices.

Following the formation of an ESG task force team (TFT) last year, composed of CEO Oh Heung-joo and executives from each business division, this year Dongkook Pharmaceutical has established an ESG committee and a permanent working organization and plans to publish a sustainability management report in the future.

A Dongkook Pharmaceutical official stated, “As domestic companies’ interest in ESG management, a global corporate management issue, is increasing, we plan to build a foundation for ESG management to meet social demands and actively disclose transparent and accurate information to stakeholders to enhance corporate trust.”

This content was produced with the assistance of AI translation services.